Skip to main content

3 Result(s)

within Paul de Souza Remove this filter Medicine & Public Health Remove this filter Pharmacology/Toxicology Remove this filter

and

  1. No Access

    Article

    First‐in‐human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies

    Background This was a phase I/IIa study to investigate the tolerability, efficacy and pharmacokinetics (PK)/ pharmacodynamics (PD) of CRLX301, CDP-based nanoparticle formulation of docetaxel. Methods The study wa...

    Sarina A. Piha-Paul, Kyaw Z. Thein, Paul De Souza… in Investigational New Drugs (2021)

  2. No Access

    Article

    A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers

    Background The MET tyrosine kinase and its ligand, hepatocyte growth factor (HGF) also known as scatter factor, are associated with tumourigenesis and metastasis by promotion of scattering, proliferation, angioge...

    Aflah Roohullah, Adam Cooper, Anna J. Lomax, Jennifer Aung… in Investigational New Drugs (2018)

  3. No Access

    Article

    A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors

    Purpose: This dose escalation study aimed to determine the recommended doses, toxicity and pharmacokinetics of oxaliplatin and gemcitabine given on days 1 and 8 every 21 days. This schedu...

    Hui K. Gan, Paul L. Mitchell, Peter Galettis… in Cancer Chemotherapy and Pharmacology (2006)